Analyst Price Targets — MMSI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 31, 2026 12:58 pm | Michael Petusky | Barrington | $114.00 | $84.22 | TheFly | Merit Medical price target raised to $114 from $107 at Barrington |
| July 31, 2026 12:51 pm | John Young | Canaccord Genuity | $94.00 | $84.42 | StreetInsider | Merit Medical Systems, Inc. (MMSI) PT Raised to $94 at Canaccord |
| July 31, 2026 12:48 pm | — | Raymond James | $100.00 | $84.06 | TheFly | Merit Medical price target raised to $100 from $83 at Raymond James |
| July 31, 2026 12:06 pm | Sam Eiber | BTIG | $105.00 | $84.27 | TheFly | Merit Medical price target raised to $105 from $100 at BTIG |
| July 31, 2026 11:24 am | Mike Matson | Needham | $101.00 | $83.35 | StreetInsider | Merit Medical Systems, Inc. (MMSI) PT Raised to $101 at Needham |
| July 31, 2026 11:20 am | — | Robert W. Baird | $98.00 | $83.35 | TheFly | Merit Medical price target raised to $98 from $89 at Baird |
| May 1, 2026 12:51 pm | David Rescott | Robert W. Baird | $83.00 | $64.61 | TheFly | Merit Medical price target lowered to $83 from $92 at Baird |
| April 20, 2026 11:44 am | Michael Petusky | Compass Point | $107.00 | $70.93 | TheFly | Merit Medical price target lowered to $107 from $109 at Barrington |
| April 17, 2026 11:43 am | — | Piper Sandler | $96.00 | $70.10 | TheFly | Merit Medical price target lowered to $96 from $106 at Piper Sandler |
| February 26, 2026 10:11 am | Larry Biegelsen | Wells Fargo | $78.00 | $79.23 | StreetInsider | Wells Fargo Downgrades Merit Medical Systems, Inc. (MMSI) to Equal Weight |
Latest News for MMSI
Freestone Grove Partners LP purchased a new position in Merit Medical Systems, Inc. (NASDAQ: MMSI) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,554 shares of the medical instruments supplier's stock, valued at approximately $1,148,000. Other hedge funds and other
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
American Capital Management Inc. acquired a new stake in Merit Medical Systems, Inc. (NASDAQ: MMSI) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 104,967 shares of the medical instruments supplier's stock, valued at approximately $7,278,000. American Capital Management
Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.
Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MMSI.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.